Could a Clot-Busting drug boost heart attack recovery?
NCT ID NCT03335839
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested whether giving a low dose of the clot-busting drug tPA directly into the heart arteries, during standard angioplasty, improves blood flow and reduces complications in people having a major heart attack. 210 patients were enrolled. The goal was to see if this approach could reduce heart damage and improve outcomes.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
tissue plasminogen activator (tPA)
What this could lead to
If it works, this could improve blood flow and reduce heart damage during a heart attack, potentially lowering the risk of death or heart failure.
What could go wrong
This is a completed Phase 3 trial with 210 participants, so results are limited. Adding tPA may increase bleeding risk, and the benefit may not be large enough to change standard care.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYOCARDIAL INFARCTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Hamilton General Hospital
Hamilton, Ontario, L8L2X2, Canada
-
University of Alberta - Mazankowski Alberta Heart Insitute
Edmonton, Alberta, T6G 2B7, Canada
-
University of Calgary - Foothills Medical Centre
Calgary, Alberta, T2N 4Z6, Canada